Simcere Pharma
Simcere Pharma is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market.
Launch date
Employees
Market cap
€1.8b
Enterprise valuation
€1.6b (Public information from Sep 2024)
Share price
HKD6.78 2096.HK
China (HQ)
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 4.5b | 5.0b | 6.3b | 6.6b | 958m | 1.1b | 1.3b |
% growth | (10 %) | 11 % | 26 % | 5 % | (86 %) | 14 % | 14 % |
EBITDA | 788m | 940m | 1.1b | 1.1b | 192m | 235m | 274m |
% EBITDA margin | 17 % | 19 % | 17 % | 17 % | 20 % | 21 % | 22 % |
Profit | 670m | 1.5b | 933m | 715m | 131m | 173m | 208m |
% profit margin | 15 % | 30 % | 15 % | 11 % | 14 % | 16 % | 17 % |
EV / revenue | 0.7x | 0.6x | 0.6x | 0.3x | 1.7x | 1.4x | 1.2x |
EV / EBITDA | 3.8x | 3.1x | 3.5x | 2.0x | 8.4x | 6.5x | 5.3x |
R&D budget | 1.1b | 1.4b | 1.7b | 1.6b | - | - | - |
R&D % of revenue | 25 % | 28 % | 27 % | 24 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Growth Equity VC | |
N/A | N/A | IPO | |
* | $135m Valuation: $1.2b 1.3x EV/LTM Revenues 7.8x EV/LTM EBITDA | Post IPO Equity | |
Total Funding | - |
Recent News about Simcere Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.